Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rx Mobile Devices Promos: Benefits Often More Prominent Than Risks

Executive Summary

In an analysis of direct-to-consumer mobile promotions, FDA found that risks and benefits are not equally prominent and accessible in the communications and their landing pages.

You may also be interested in...



Rx Ad Studies Target Risk Info Location, Efficacy Framing, Oncology Products

Flurry of new studies brings tally of FDA research projects on Rx drug promotion to 43; the 14 in progress and 7 pending peer review or recently published have a total cost of $15.5m.

Contrave TV Ad's Slimmed Down Adverse Events Draw FDA Rebuke

Referencing opioids and suicidal thoughts is not sufficient, US regulators say; letter comes as Orexigen has seen an upsurge in Contrave prescriptions.

FDA’s Twitter Formula Allows Tweets About Products Without Excessive Risks

FDA’s draft guidance on presenting product information on social media platforms with character space limitations includes an equation for sending a tweet.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS121055

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel